Loading...

吉非替尼治疗EGFR基因突变状态不明的青年晚期肺腺癌疗效分析

BACKGROUND AND OBJECTIVE: Lung cancer in young patients (less or equal to 45 years) is relatively rare. We explored the efficacy and survival of Gefitinib for young patients with unknown epidermal growth factor receptor (EGFR) gene mutation of advanced lung adenocarcinoma. METHODS: The clinical data...

Full description

Saved in:
Bibliographic Details
Published in:Zhongguo Fei Ai Za Zhi
Format: Artigo
Language:Inglês
Published: 中国肺癌杂志编辑部 2014
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000448/
https://ncbi.nlm.nih.gov/pubmed/24854557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2014.05.06
Tags: Add Tag
No Tags, Be the first to tag this record!